Abivax

Paris, France

Abivax develops medicines that alter the body's natural immune system mechanisms.

$45.0M raised

May 2026

Post-IPO Equity

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Abivax raised?

Abivax has raised $45.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in May 2026.

Who are Abivax's investors?

Abivax's investors include TCG Crossover, Samsara BioCapital, Sofinnova Partners, Great Point Partners, Deerfield.

Where is Abivax headquartered?

Abivax is headquartered in Paris, France.

What does Abivax do?

Abivax develops medicines that alter the body's natural immune system mechanisms.

What stage is Abivax at?

Abivax is at the Post-IPO Equity stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated May 5, 2026.

MLA

"Abivax — Funding & Investors." VCBacked, May 5, 2026, https://www.vcbacked.co/company/abivax. Accessed July 2, 2026.

APA

VCBacked. (2026). Abivax — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/abivax

Wikipedia (cite web)

{{cite web |title=Abivax — Funding & Investors |url=https://www.vcbacked.co/company/abivax |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated May 5, 2026.